Mont Royal Resources Limited (ASX:MRZ) Suspended from Quotation
Mont Royal Resources Limited (ASX:MRZ) suspends its securities from quotation pending a proposed re-compliance transaction.
Tag: Regulatory News & Compliance
Desert Metals Limited (ASX:DM1) Announces Trading Halt
Desert Metals Limited (ASX:DM1) requests a trading halt pending an upcoming announcement, potentially related to a capital raise.
Artemis Resources Limited (ASX:ARV) Clarifies Permitting for Radio Hill
Artemis Resources (ASX:ARV) clarifies permitting activities for the Radio Hill processing plant and updates on the Carlow Castle Mineral Resource Estimate.
ACORN CAPITAL INVESTMENT FUND LIMITED (ASX:ACQ) Suspended from Quotation
ACORN CAPITAL INVESTMENT FUND LIMITED (ASX:ACQ) is suspended from quotation for not lodging the required periodic report by the due date.
Neurizon Therapeutics Limited (ASX:NUZ) Receives FDA Guidance on NUZ-001 IND Application
Neurizon Therapeutics Limited (ASX:NUZ) receives FDA guidance on its IND application for NUZ-001, requesting additional animal exposure data.
Smart Parking Limited (ASX:SPZ) Requests Trading Halt
Smart Parking Limited (ASX:SPZ) requests a trading halt until 19 February 2025 pending its accelerated entitlement offer outcome.
Recce Pharmaceuticals (ASX:RCE) Reports Successful Phase II Trial Results
Recce Pharmaceuticals (ASX:RCE) reports successful Phase II trial of RECCE®327 Gel, advancing to Phase III for ABSSSI treatment.
Invictus Energy Ltd (ASX:IVZ) Advances Pilot Gas Production with ESIA Approval
Invictus Energy Ltd (ASX:IVZ) secures ESIA approval for pilot gas production at Cabora Bassa, advancing gas extraction and power projects in Zimbabwe.
Swoop Holdings Limited (ASX:SWP) Extends Takeover Offer for Vonex Limited
Swoop Holdings Limited (ASX:SWP) extends its off-market takeover offer for Vonex Limited until 21 February 2025.
Avecho Biotechnology Limited (ASX:AVE) Addresses Recent Securities Trading
Avecho Biotechnology Limited (ASX:AVE) addresses recent securities trading, citing potential Phase III trial success and confirms compliance with ASX listing rules.